This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Antonio Llombart-Cussac, MD; Xavier Pivot, MD
Centre Antoine Lacassagne 36 voie Romaine 06000 Nice, France

Marc Spielmann, MD
Villejuif, France

Arch Dermatol. 1997;133(11):1466-1467.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The taxoids, docetaxel and paclitaxel, are a new family of effective chemotherapy agents. Paclitaxel provides a survival benefit in patients with advanced ovarian cancer, and both are the most effective drugs in patients with breast cancer and anthracycline-resistant disease. Nail disorders are commonly observed in patients treated with docetaxel.¹ We have observed a striking example of multiple transverse loss of the nail plate from all fingernails and toenails in a woman receiving a docetaxel infusion for treatment of advanced breast cancer.

Report of a Case.

A 37-year-old woman was treated for an infiltrating ductal carcinoma of the breast by mastectomy. Adjuvant treatment included standard chemotherapy (fluorouracil, epirubicin, and cyclophosphamide), medical castration, and radiotherapy of the chest wall and supraclavicular area. Sixteen months later, a chest wall recurrence developed. A second-line chemotherapy regimen for advanced breast cancer was administered. The treatment consisted of a combination of docetaxel, 75 mg/m² . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?